Doherty, Mark T. http://orcid.org/0000-0003-3009-7969
Aris, Emmanuel http://orcid.org/0000-0001-8640-1742
Servotte, Nathalie
Beck, Ekkehard http://orcid.org/0000-0002-2022-9190
Funding for this research was provided by:
GlaxoSmithKline
Article History
Received: 26 January 2022
Accepted: 6 March 2022
First Online: 28 May 2022
Declarations
:
: Ekkehard Beck, Mark Doherty, Nathalie Servotte, and Emmanuel Aris are employed by and hold shares in the GSK group of companies.
: The study was assessed by an internal Global Medical Affairs Team and endorsed as appropriate and proportionate (eTrack Number: ODA-ABOVEB-003). As the study involved secondary data collection (de-identified insurance claims) no further ethical review was required.
: This study involved analyses of an Accountability Act-compliant secondary database, thus no informed consent was feasible or necessary.